At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Lenvatinib combined with gemox +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open, Two-cohort Phase 2 Study of Toripalimab(PD1) Combined With Lenvatnib, or Gemox Chemotherapy Combined With Lenvatinib as First-line Therapy in Patients With Advanced or Unresectable Intrahepatic Cholangiocarcinoma
In Brief
A Phase 2 clinical trial evaluating Lenvatinib combined with gemox and Toripalimab combined with lenvatinib for Cholangiocarcinoma, Intrahepatic. Completed, enrolled 61 participants across 2 sites.
Detailed Summary
We aim to explore the effects and safety of the two cohorts of toripalimab combined with lenvatinib or gemox combined with lenvatinib as first-line therapy in advanced or unresectable intrahepatic cholangiocarcinoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholangiocarcinoma, Intrahepatic
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartMar 2020
First PostedApr 2020
Primary CompletionSep 2023
TodayJul 2026
First PostedApr 24, 2020
Enrollment StartMar 6, 2020
Primary CompletionSep 1, 2023
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 6.2 years ago
Interventions
Lenvatinib combined with gemoxdrug
Arm2: Lenvatinib + gemox
Toripalimab combined with lenvatinibdrug
Toripalimab combined with lenvatinib